<DOC>
	<DOCNO>NCT01080300</DOCNO>
	<brief_summary>Depomed 's Gabapentin Extended Release investigational , extended release formulation Gabapentin study treatment Hot Flashes/Hot Flushes postmenopausal woman</brief_summary>
	<brief_title>Breeze3 : Study Gabapentin Extended Release Treatment Vasomotor Symptoms ( Hot Flashes ) Postmenopausal Women</brief_title>
	<detailed_description>The primary study objective ass efficacy G-ER dose 1800mg daily ( 600mg AM , 1200mg PM ) , compare placebo reduce average daily frequency severity score moderate severe hot flash postmenopausal woman week 4 &amp; 12 efficacy treatment period , compare baseline .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Generally healthy , postmenopausal woman seek treatment hot flash Patients use hormone replacement therapy ( HRT ) must willing discontinue treatment Patients must experience moderate severe hot flash Patients must able sign inform consent Patients must able enter simple command complete questionnaire frequency severity hot flash use electronic diary Other inclusion apply . Patients hypersensitivity Gabapentin Patients severe chronic diarrhea , chronic constipation , uncontrolled irritable bowel syndrome ( IBS ) unexplained weight loss Patients treat estrogen pellet injectable progestin drug therapy within 6 month . Patients currently treat Gabapentin Pregabalin indication , include vasomotor symptoms Other exclusion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hot Flushes</keyword>
	<keyword>Vasomotor Symptoms</keyword>
	<keyword>Menopausal Hot Flashes</keyword>
</DOC>